GlassScriptPhysician profile
Leonide Brunot
NPI 1659094050
$436.69
in general payments reported to CMS, 2019-2025
11 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $43.01 · 2023: $137 · 2024: $144 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $158.27 | 2022-2025 | Tecvayli, Darzalex |
| Incyte Corporation | $53.01 | 2024 | Jakafi |
| Btg International INC. | $47.03 | 2023-2025 | Voraxaze |
| Adaptive Biotechnologies Corporation | $30.56 | 2023 | Clonoseq |
| Ipsen Biopharmaceuticals, INC | $27.19 | 2024 | Onivyde, Somatuline Depot |
| Bayer Healthcare Pharmaceuticals INC. | $23.80 | 2023 | |
| Grifols USA, LLC | $23.11 | 2025 | Gamunex-C |
| Astrazeneca Pharmaceuticals LP | $20.14 | 2023 | Enhertu |
| Lundbeck LLC | $18.77 | 2025 | Vyepti |
| Daiichi Sankyo INC. | $17.74 | 2023 | Enhertu |
| Melinta Therapeutics, LLC | $17.07 | 2025 | Kimyrsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonide Brunot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.